Seeing Is Believing
 Healthcare - Sector
                            Healthcare - Sector
                    
                    SRPT is currently covered by 24 analysts with an average price target of $48.94. This is a potential upside of $25.69 (110.49%) from yesterday's end of day stock price of $23.25.
Sarepta Therapeutics's activity chart (see below) currently has 809 price targets and 684 ratings on display. The stock rating distribution of SRPT is 57.43% BUY, 14.85% SELL and 27.72% HOLD.
Analysts average stock forecasts to be materialized ratio is 54.8% with an average time for these price targets to be met of 249.2 days.
Highest price target for SRPT is $98, Lowest price target is $5, average price target is $31.48.
Most recent stock forecast was given by KOSTAS BILIOURIS from BMO on 21-Sep-2025. First documented stock forecast 20-Mar-2013.
Currently out of the existing stock ratings of SRPT, 58 are a BUY (57.43%), 15 are a SELL (14.85%), 28 are a HOLD (27.72%).
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date
Price targets met ratio
Average potential upside
Average Days to Hit Target
Performance score
Buy
$50
$27.19 (119.20%)
$50
1 months 8 days ago
(21-Sep-2025)
0/10 (0%)
$31.35 (168.10%)
Buy
$22
$-0.81 (-3.55%)
$98
1 months 15 days ago
(14-Sep-2025)
16/25 (64%)
$4.53 (25.93%)
229
Hold
$15
$-7.81 (-34.24%)
$160
1 months 21 days ago
(08-Sep-2025)
15/20 (75%)
$-2.64 (-14.97%)
133
Sell
$5
$-17.81 (-78.08%)
$40
2 months 5 days ago
(24-Aug-2025)
8/11 (72.73%)
$-13.06 (-72.31%)
55
Sell
$16
$-6.81 (-29.86%)
$10
2 months 9 days ago
(20-Aug-2025)
4/16 (25%)
$-4.06 (-20.24%)
246
What is SRPT (Sarepta Therapeutics) average time for price targets to be met?
Which analyst has the current highest performing score on SRPT (Sarepta Therapeutics) with a proven track record?
Which analyst has the most public recommendations on SRPT (Sarepta Therapeutics)?
Which analyst is the currently most bullish on SRPT (Sarepta Therapeutics)?
Which analyst is the currently most reserved on SRPT (Sarepta Therapeutics)?